Clinical development of phosphatidylinositol-3 kinase pathway inhibitors
about
Pharmacodynamic Biomarker Development for PI3K Pathway TherapeuticsPhosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.Role of a novel benzoxazine derivative in the chemosensitization of colon cancer.
P2860
Clinical development of phosphatidylinositol-3 kinase pathway inhibitors
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Clinical development of phosphatidylinositol-3 kinase pathway inhibitors
@ast
Clinical development of phosphatidylinositol-3 kinase pathway inhibitors
@en
type
label
Clinical development of phosphatidylinositol-3 kinase pathway inhibitors
@ast
Clinical development of phosphatidylinositol-3 kinase pathway inhibitors
@en
prefLabel
Clinical development of phosphatidylinositol-3 kinase pathway inhibitors
@ast
Clinical development of phosphatidylinositol-3 kinase pathway inhibitors
@en
P2860
P356
P1476
Clinical development of phosphatidylinositol-3 kinase pathway inhibitors
@en
P2093
Carlos L Arteaga
P2860
P304
P356
10.1007/82_2010_54
P577
2010-01-01T00:00:00Z